TY - JOUR
T1 - Long term activity of vemurafenib in cancers with BRAF mutations
T2 - the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
AU - Blay, J. Y.
AU - Cropet, C.
AU - Mansard, S.
AU - Loriot, Y.
AU - De La Fouchardière, C.
AU - Haroche, J.
AU - Topart, D.
AU - Tougeron, D.
AU - You, B.
AU - Italiano, A.
AU - Le Brun-Ly, V.
AU - Ferrero, J. M.
AU - Penel, N.
AU - Fabbro, M.
AU - Troussard, X.
AU - Malka, D.
AU - Ray-Coquard, I.
AU - Leboulleux, S.
AU - Fléchon, A.
AU - Maubec, E.
AU - Charles, J.
AU - Dalle, S.
AU - Taieb, S.
AU - Garcia, G. C.T.E.
AU - Mandache, A. M.
AU - Colignon, N.
AU - Gavrel, M.
AU - Nowak, F.
AU - Hoog Labouret, N.
AU - Mahier Aït Oukhatar, C.
AU - Gomez-Roca, C.
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background: BRAF inhibitors are approved in BRAFV600-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim–Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent vemurafenib given in the AcSé vemurafenib basket study to patients with various BRAF-mutated advanced tumours other than BRAFV600-mutated melanoma and NSCLC. Patients and methods: Patients with advanced tumours other than BRAFV600E melanoma and progressing after standard treatment were eligible for inclusion in nine cohorts (including a miscellaneous cohort) and received oral vemurafenib 960 mg two times daily. The primary endpoint was the objective response rate (ORR) estimated with a Bayesian design. The secondary outcomes were disease control rate, duration of response, progression-free survival (PFS), overall survival (OS), and vemurafenib safety. Results: A total of 98 advanced patients with various solid or haematological cancers, 88 with BRAFV600 mutations and 10 with BRAFnonV600 mutations, were included. The median follow-up duration was 47.7 months. The Bayesian estimate of ORR was 89.7% in hairy cell leukaemias (HCLs), 33.3% in the glioblastomas cohort, 18.2% in cholangiocarcinomas, 80.0% in ECD, 50.0% in ovarian cancers, 50.0% in xanthoastrocytomas, 66.7% in gangliogliomas, and 60.0% in sarcomas. The median PFS of the whole series was 8.8 months. The 12-, 24-, and 36-month PFS rates were 42.2%, 23.8%, and 17.9%, respectively. Overall, 54 patients died with a median OS of 25.9 months, with a projected 4-year OS of 40%. Adverse events were similar to those previously reported with vemurafenib. Conclusion: Responses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
AB - Background: BRAF inhibitors are approved in BRAFV600-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim–Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent vemurafenib given in the AcSé vemurafenib basket study to patients with various BRAF-mutated advanced tumours other than BRAFV600-mutated melanoma and NSCLC. Patients and methods: Patients with advanced tumours other than BRAFV600E melanoma and progressing after standard treatment were eligible for inclusion in nine cohorts (including a miscellaneous cohort) and received oral vemurafenib 960 mg two times daily. The primary endpoint was the objective response rate (ORR) estimated with a Bayesian design. The secondary outcomes were disease control rate, duration of response, progression-free survival (PFS), overall survival (OS), and vemurafenib safety. Results: A total of 98 advanced patients with various solid or haematological cancers, 88 with BRAFV600 mutations and 10 with BRAFnonV600 mutations, were included. The median follow-up duration was 47.7 months. The Bayesian estimate of ORR was 89.7% in hairy cell leukaemias (HCLs), 33.3% in the glioblastomas cohort, 18.2% in cholangiocarcinomas, 80.0% in ECD, 50.0% in ovarian cancers, 50.0% in xanthoastrocytomas, 66.7% in gangliogliomas, and 60.0% in sarcomas. The median PFS of the whole series was 8.8 months. The 12-, 24-, and 36-month PFS rates were 42.2%, 23.8%, and 17.9%, respectively. Overall, 54 patients died with a median OS of 25.9 months, with a projected 4-year OS of 40%. Adverse events were similar to those previously reported with vemurafenib. Conclusion: Responses and prolonged PFS were observed in many tumours with BRAF mutations, including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas. Although not all cancer types responded, vemurafenib is an agnostic oncogene therapy of cancers.
KW - BRAF mutations
KW - efficacy
KW - objective response rate
KW - overall survival
KW - progression-free survival
KW - safety
KW - vemurafenib
UR - http://www.scopus.com/inward/record.url?scp=85175421640&partnerID=8YFLogxK
U2 - 10.1016/j.esmoop.2023.102038
DO - 10.1016/j.esmoop.2023.102038
M3 - Article
C2 - 37922690
AN - SCOPUS:85175421640
SN - 2059-7029
VL - 8
JO - ESMO Open
JF - ESMO Open
IS - 6
M1 - 102038
ER -